J. Nyberg

发表

Ethically Attractive Dose‐Finding Designs for Drugs With a Narrow Therapeutic Index

M. Karlsson, R. Lledo-Garcia, S. Hennig, 2012, Journal of clinical pharmacology.

Using Bayesian belief networks in adaptive management

B. Marcot, J. Nyberg, Randy Sulyma, 2006 .

Analysis of opioid consumption in clinical trials: a simulation based analysis of power of four approaches

L. Christrup, J. Nyberg, R. V. Juul, 2017, Journal of Pharmacokinetics and Pharmacodynamics.

Using Bayesian belief networks in adaptive management1

Bruce G. Marcot, B. Marcot, J. Nyberg, 2007 .

The effect of Fisher information matrix approximation methods in population optimal design calculations

Eric A. Strömberg, J. Nyberg, A. Hooker, 2016, Journal of Pharmacokinetics and Pharmacodynamics.

Optimizing disease progression study designs for drug effect discrimination

M. Karlsson, S. Hennig, J. Nyberg, 2013, Journal of Pharmacokinetics and Pharmacodynamics.

Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies

M. Karlsson, E. Plan, J. Nyberg, 2019, The AAPS Journal.

A Comparison of Automatic Differentiation and Continuous Sensitivity Analysis for Derivatives of Differential Equation Solutions pdf

Vaibhav Dixit, Christopher Rackauckas, Joakim Nyberg, 2018, 2021 IEEE High Performance Extreme Computing Conference (HPEC).

A quantitative approach to the choice of number of samples for percentile estimation in bootstrap and visual predictive check analyses

J. Nyberg, E. Jonsson, 2022, CPT: pharmacometrics & systems pharmacology.

Accelerated Predictive Healthcare Analytics with Pumas, A High Performance Pharmaceutical Modeling and Simulation Platform

Patrick Kofod Mogensen, Andreas Noack, Joakim Nyberg, 2020, bioRxiv.

Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

G. K. Moghaddam, M. Menden, S. Wicha, 2022, Pharmaceutics.

Edoxaban Exposure‐Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep‐Vein Thrombosis or Pulmonary Embolism

S. Jönsson, J. Nyberg, O. Yin, 2016, CPT: pharmacometrics & systems pharmacology.

Population pharmacokinetics of edoxaban in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism--the Hokusai-VTE phase 3 study.

Raymond Miller, M. Karlsson, S. Jönsson, 2015, British journal of clinical pharmacology.

Adaptive‐Optimal Design in PET Occupancy Studies

R Gomeni, S Zamuner, V L Di Iorio, 2010, Clinical pharmacology and therapeutics.

Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations

K. Venkatakrishnan, O. Papasouliotis, R. Strotmann, 2022, Cancer Chemotherapy and Pharmacology.

Application of ED-optimality to screening experiments for analgesic compounds in an experimental model of neuropathic pain

M. Danhof, A. Taneja, O. Della Pasqua, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

Exposure‐Response Analyses Supporting Ticagrelor Dosing Recommendation in Patients With Prior Myocardial Infarction

D. Stanski, R. Storey, J. Nyberg, 2017, Journal of clinical pharmacology.

The Strategic Use of Marketing as Revenue Management in Finnish Start-up Companies (Available on Internet)

J. Nyberg, 2016 .

Optimizing disease progression study designs for drug effect discrimination

M. Karlsson, S. Hennig, J. Nyberg, 2013, Journal of Pharmacokinetics and Pharmacodynamics.

A Pharmacokinetic-Pharmacodynamic Model of Morphine Exposure and Subsequent Morphine Consumption in Postoperative Pain

L. Christrup, J. Nyberg, M. Kreilgaard, 2016, Pharmaceutical Research.

An introduction to the full random effects model

M. Karlsson, J. Nyberg, E. Jonsson, 2022, CPT: pharmacometrics & systems pharmacology.

PopED: An extended, parallelized, nonlinear mixed effects models optimal design tool

Andrew C. Hooker, Mats O. Karlsson, Stefanie Hennig, 2012, Comput. Methods Programs Biomed..

Optimal Design in Population Kinetic Experiments by Set-Valued Methods

Andrew C. Hooker, Warwick Tucker, Joakim Nyberg, 2011, The AAPS Journal.

Optimised protocol design for the screening of analgesic compounds in neuropathic pain

M. Danhof, A. Taneja, O. Della Pasqua, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

Population Volume Kinetics in Volunteers: Reply.

C. Svensen, J. Nyberg, M. Kinsky, 2020, Anesthesiology.

Population Kinetics of 0.9% Saline Distribution in Hemorrhaged Awake and Isoflurane-anesthetized Volunteers.

D. Prough, C. Svensen, J. Nyberg, 2019, Anesthesiology.

A Pharmacokinetic-Pharmacodynamic Model of Morphine Exposure and Subsequent Morphine Consumption in Postoperative Pain

S. Rasmussen, L. Christrup, J. Nyberg, 2016, Pharmaceutical Research.

Population Pharmacokinetic Modeling and Optimal Sampling Strategy for Bayesian Estimation of Amikacin Exposure in Critically Ill Septic Patients

Joakim Nyberg, Frédérique Jacobs, Flora T Musuamba, 2010, Therapeutic drug monitoring.

Rapid Sample Size Calculations for a Defined Likelihood Ratio Test-Based Power in Mixed-Effects Models

M. Karlsson, J. Nyberg, C. Vong, 2012, The AAPS Journal.

The lasso—a novel method for predictive covariate model building in nonlinear mixed effects models

E. Niclas Jonsson, Ola Caster, Joakim Nyberg, 2007, Journal of Pharmacokinetics and Pharmacodynamics.

Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies.

Stephen Duffull, France Mentré, Sergei Leonov, 2015, British journal of clinical pharmacology.

Optimization of the intravenous glucose tolerance test in T2DM patients using optimal experimental design

Andrew C. Hooker, Mats O. Karlsson, Joakim Nyberg, 2009, Journal of Pharmacokinetics and Pharmacodynamics.

Properties of the full random effect modelling approach with missing covariates

M. Karlsson, J. Nyberg, E. Jonsson, 2019, bioRxiv.

Serial correlation in optimal design for nonlinear mixed effects models

M. Karlsson, J. Nyberg, A. Hooker, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

Simultaneous optimal experimental design on dose and sample times

Andrew C. Hooker, Mats O. Karlsson, Joakim Nyberg, 2009, Journal of Pharmacokinetics and Pharmacodynamics.

A Comparison of Automatic Differentiation and Continuous Sensitivity Analysis for Derivatives of Differential Equation Solutions

Vaibhav Dixit, Christopher Rackauckas, Joakim Nyberg, 2018, 2021 IEEE High Performance Extreme Computing Conference (HPEC).

Trial Treatment Length Optimization With an Emphasis on Disease Progression Studies

Stefanie Hennig, Joakim Nyberg, Mats O Karlsson, 2009, Journal of clinical pharmacology.

Application of the Optimal Design Approach to Improve a Pretransplant Drug Dose Finding Design for Ciclosporin

Stefanie Hennig, Joakim Nyberg, Mats O Karlsson, 2012, Journal of clinical pharmacology.

584P Tepotinib exposure-response analyses of safety and efficacy in patients with solid tumours

R. Anziano, P. Paik, O. Papasouliotis, 2020 .

Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model

Andrew C. Hooker, Mats O. Karlsson, Joakim Nyberg, 2014, Journal of Pharmacokinetics and Pharmacodynamics.

Properties of the full random‐effect modeling approach with missing covariate data

J. Nyberg, E. Niclas Jonsson, Mats O. Karlsson, 2023, Statistics in medicine.

Population Pharmacokinetic Modeling and Optimal Sampling Strategy for Bayesian Estimation of Amikacin Exposure in Critically Ill Septic Patients

F. Taccone, P. Laterre, J. Nyberg, 2010, Therapeutic drug monitoring.

Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors

J. Nyberg, G. E. Blouse, U. Simonsson, 2024, Clinical pharmacology and therapeutics.